comparemela.com

Latest Breaking News On - Dystrophy - Page 8 : comparemela.com

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the

Switzerland generalUnited statesUnited kingdomEric hoffmanEva kaliasReveragen biopharmaDario eklundReveragen biopharma incLife science allianceSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthDuchenne research fundFoundation to eradicate duchenneDrug administrationSanthera pharmaceuticals holding

Vertex, Entrada To Develop Endosomal Escape Vehicle Therapeutics For Myotonic Dystrophy Type 1

CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) and Entrada Therapeutics Inc. (TRDA) have established collaboration to discover and develop endosomal escape vehicle therapeutics

United statesVertex pharmaceuticals incEntrada therapeutics incEntrada therapeuticsMyotonic dystrophy type

Vertex Pharmaceuticals Incorporated: Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

- Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone payments and royalties - - Global collaboration includes ENTR-701, Entrada's EEV-investigational

United statesUnited kingdomCity ofHeather nicholsDavid altshulerKarla macdonaldDipal doshiSusie lisaGlobal researchVertex pharmaceuticals incorporatedExchange commissionEntrada therapeutics incVertex pharmaceuticals incorporated nasdaqCorporate affairsPharmaceuticals incorporatedEntrada therapeutics

AMO Pharma Limited: AMO Pharma Announces Completion of Enrollment in REACH-CDM Study in Congenital Myotonic Dystrophy

Company also announces additional private equity investment LONDON, Dec. 6, 2022 /PRNewswire/ AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on

City ofUnited kingdomIbs mahmoodJoseph horriganKostenloser wertpapierhandelBill berryPharma limitedBerry company public relationsChief medical officerChief executive officer

Santhera Pharmaceuticals Holding AG: European Medicines Agency Validates Santhera s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Pratteln, Switzerland, October 31, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone

Switzerland generalUnited statesUnited kingdomShabir hashamEric hoffmanEva kaliasReveragen biopharmaLife science allianceSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthEuropean commissionDuchenne research fundFoundation to eradicate duchenneDrug administrationSanthera pharmaceuticals holding

vimarsana © 2020. All Rights Reserved.